NCT04007120View on ClinicalTrials.gov

Open-label Study of Inhaled RVT-1601 in Preterm Infants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

May 29, 2020

Study Completion Date

May 29, 2020

Conditions
Respiratory Morbidities of Prematurity (RMP)
Interventions
DRUG

RVT-1601

Inhaled RVT-1601 administered once daily over two days

Trial Locations (1)

92123

Sharp Mary Birch Hospital for Women & Newborns, San Diego

All Listed Sponsors
collaborator

Respivant Sciences Inc.

INDUSTRY

lead

Respivant Sciences GmbH

INDUSTRY

NCT04007120 - Open-label Study of Inhaled RVT-1601 in Preterm Infants | Biotech Hunter | Biotech Hunter